We observed that neither a 10 fold increase in progesterone receptor nor a 2 fold increase in Cox 2 inhibition were effective in preventing the PRA/PRB increase at levels of NF-κB activation that might occur during subclinical infection. The gene discussed is NFKB1; the disease is infection.